CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
Farmaexplorer.it
Xagena Salute

Search results for "Brilique"

American Heart Association ( AHA ) and American College of Cardiology ( ACC ) have updated the guideline for the management of patients with non–ST-elevation acute coronary syndromes ( NSTE-ACS ). T ...


The results of the phase IV ATLANTIC study, which indicates that the profile of Ticagrelor ( Brilinta, Brilique ) is comparable whether administered in a pre-hospital or in-hospital setting to ST segm ...


Morphine is recommended in patients with ST-segment-elevation myocardial infarction, including those undergoing primary percutaneous coronary intervention ( PCI ). Suboptimal antiplatelet effect durin ...


The results of a sub-analysis of the PEGASUS-TIMI 54 study, which evaluated reasons and rates for discontinuation of Ticagrelor ( Brilinta, Brilique ) in patients with a history of myocardial infarcti ...


The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. Researchers have investigated the efficacy and safety of Ticagrelor ( Brili ...


A sub-analysis of the PEGASUS-TIMI 54 study, assessing the effect of Ticagrelor ( Brilinta, Brilique ) in reducing atherothrombotic events in post-myocardial infarction patients, based on the time fro ...


Ticagrelor ( Brilinta, Brilique ) administered in the ambulance reduces ischaemic events 24 hours after primary percutaneous coronary intervention ( PCI ), according to findings from the ATLANTIC-H24 ...


At the European Society of Cardiology Congress 2019, researchers from Brigham and Women's Hospital and Greater Paris University Hospitals - AP-HP/Université de Paris, have presented the results from T ...


The combination of Ticagrelor ( Brilique ) and Aspirin ( Acetylsalicylic acid ) reduces ischaemic events compared with Aspirin alone in patients with stable coronary artery disease and diabetes. The ...


Prasugrel ( Efient ) is superior to Ticagrelor ( Brilique ) for reducing ischaemic events in patients with acute coronary syndrome and a planned invasive strategy. The results of the ISAR-REACT 5 tr ...